The UK has issued further guidance for companies wishing to parallel import medicines from the EU to the UK from January 2025, including rules on the “UK-only” label requirement and when companies can begin making updates to their labeling and packaging.
Under the UK’s post-Brexit licensing scheme, medicines approved in a member state of the EU or European Economic Area can be parallel imported into the UK “as long as the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?